Trials that use: Cochran-Mantel-Haenszel test
New to this method? Read the tutorial →
89 results
- METEORIndependent statistical analysis of the METEOR phase 3 trial of cabozantinib versus everolimus in metastatic renal cell carcinoma, including progression-free survival, overall survival, objective response rate, trial design, and statistical methodology.
- ML18147Independent statistical analysis of ML18147, a randomized phase 3 trial of bevacizumab plus chemotherapy in metastatic colorectal cancer, including overall survival, progression-free survival, response rate, statistical methodology, safety, and interpretation.
- MONALEESA-2Complete statistical analysis of MONALEESA-2, the randomized phase 3 trial of ribociclib plus letrozole versus placebo plus letrozole in postmenopausal women with advanced or metastatic breast cancer.
- MONALEESA-7Independent statistical analysis of MONALEESA-7, a randomized phase 3 trial of ribociclib plus endocrine therapy and goserelin versus placebo plus endocrine therapy and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced…
- MONARCH 3Independent statistical analysis of the phase 3 MONARCH 3 trial of abemaciclib plus a nonsteroidal aromatase inhibitor in postmenopausal women with breast cancer, including progression-free survival, response, health-status outcomes, methodology, safety, and…
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.
- OCEANSIndependent statistical analysis of the OCEANS phase 3 trial of carboplatin and gemcitabine plus bevacizumab versus placebo in patients with ovary, peritoneal, or fallopian tube carcinoma, including PFS, objective response, overall survival,…
- OPUSIndependent statistical analysis of the OPUS trial of cetuximab plus FOLFOX-4 versus FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer, including response, progression-free survival, overall survival, KRAS subgroup analyses, methodology, and…
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- PREVAILIndependent statistical analysis of the phase 3 PREVAIL trial of enzalutamide versus placebo in chemotherapy-naive patients with progressive metastatic prostate cancer, including time-to-event endpoints, response analyses, safety, and statistical interpretation.
- PROMISE-2Independent statistical analysis of the PROMISE-2 phase 3 trial of ALD403 (eptinezumab) for the prevention of chronic migraine, including trial design, endpoints, ANCOVA, MMRM, Cochran-Mantel-Haenszel analyses, reported results, safety, and statistical interpretation.
- PROSPERIndependent statistical analysis of the phase 3 PROSPER trial of enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer, including metastasis-free survival, secondary time-to-event endpoints, PSA response, statistical methodology, and interpretation.
- RAINBOWIndependent statistical analysis of the phase 3 RAINBOW trial of ramucirumab plus paclitaxel versus placebo plus paclitaxel in metastatic gastric adenocarcinoma, including survival, response, quality-of-life, safety, and statistical methodology.
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RATIONALE-303Independent statistical analysis of RATIONALE-303, a randomized phase 3 trial comparing tislelizumab with docetaxel in second- or third-line non-small cell lung cancer, including overall survival, response, progression-free survival, quality of life, and…
- REACHIndependent statistical analysis of the phase 3 REACH trial of ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma after sorafenib.
- REACH-2Independent statistical analysis of REACH-2, a randomized phase 3 trial of ramucirumab plus best supportive care versus placebo plus best supportive care in hepatocellular carcinoma with elevated baseline alpha-fetoprotein.
- RESORCEIndependent statistical analysis of the phase 3 RESORCE trial of regorafenib versus placebo in hepatocellular carcinoma, including overall survival, time to progression, progression-free survival, tumor response, statistical methodology, and interpretation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- SAILINGComplete statistical analysis of the SAILING phase 3 trial comparing GSK1349572 (dolutegravir) with raltegravir in antiretroviral-experienced, integrase inhibitor-naive adults with HIV infection, including its non-inferiority design, Cochran-Mantel-Haenszel analysis, risk difference, confidence interval,…
- SALSAIndependent statistical analysis of the phase 3 SALSA trial of switching to dolutegravir/lamivudine fixed-dose combination from a current antiretroviral regimen in virologically suppressed adults with HIV-1 infection.
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SKYSCRAPER-02Independent statistical analysis of SKYSCRAPER-02, a randomized phase 3 trial of tiragolumab plus atezolizumab with carboplatin and etoposide versus placebo plus atezolizumab with carboplatin and etoposide in untreated extensive-stage small cell lung…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SPOTLIGHTComplete statistical analysis of the randomized phase 3 SPOTLIGHT trial of zolbetuximab plus chemotherapy versus placebo plus chemotherapy in adults with gastric or gastroesophageal junction adenocarcinoma, including progression-free survival, overall survival, response,…
- SPRING-2Independent statistical analysis of the SPRING-2 phase 3 trial comparing dolutegravir 50 mg once daily with raltegravir 400 mg twice daily for HIV-1 infection, including its non-inferiority design, stratified Cochran-Mantel-Haenszel analysis, confidence…
- STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…
- STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.
- SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.
- TBTC Study 31Complete statistical analysis of TBTC Study 31, a randomized phase 3 trial of rifapentine-containing tuberculosis treatment-shortening regimens, including non-inferiority methodology, disease-free survival, safety, confidence intervals, and interpretation.
- TH3RESAIndependent statistical analysis of TH3RESA, a randomized phase 3 trial of trastuzumab emtansine versus treatment of physician's choice in participants with HER2-positive breast cancer who had received at least two prior HER2-directed…
- TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.
- TRANSITIONIndependent statistical analysis of the TRANSITION phase 4 trial comparing pre- and post-discharge initiation of LCZ696 in patients with heart failure with reduced ejection fraction after an acute decompensation event.
- TROPiCS-02Independent statistical analysis of TROPiCS-02, a randomized phase 3 trial of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer.
- TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…
- VIALE-AIndependent statistical analysis of the phase 3 VIALE-A trial of venetoclax plus azacitidine versus azacitidine in treatment-naive participants with acute myeloid leukemia who are ineligible for standard induction therapy.
- ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…